Myeloproliferative Neoplasms Treatment Market Accelerates Business to Gain High Revenue during 2018-2026
Myeloproliferative
Neoplasms (MPNs) are a group of rare disease, in which the bone
marrow produces excess blood cells. It can be white blood cells, red
blood cells or platelets. The overproduction of blood cells by the
bone marrow creates hindrance in the smooth flow of blood, which
leads to various symptoms such as progressive cytopenias, cachexia
and weight loss, splenomegaly, and blastic transformation. These
conditions are developed gradually over a period of time. Most people
are diagnosed after the age of 60 years, when they were accompanied
by many other health issues, makes the treatment more difficult.
The major symptoms
associated with MPNs include bleeding problem, anemia, chest pain,
fatigue, enlarged spleen, and weight loss. According to Annals of
Hematology, approximately 90% of patients has experienced
MPN-symptoms in past 12 months, wherein women are reported to have
higher overall burden than men. The treatment for myeloproliferative
neoplasms is mainly aimed to reduce the excess number of blood cells
circulation. The concept of myleoproliferative disease was first
given by hematologist Williom Dameshek in 1950. However, in 2008,
World Health Organization (WHO) classified hematologic malignancies
and renamed myloproliferative diseases to myeloproliferative
neoplasms.
Request For a
Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/930
Rising
awareness of molecular abnormalities and cellular pathways involved
in the pathogenesis of MPNs is expected to facilitate the development
of novel drugs, propels the Myeloproliferative Neoplasms treatment
market growth in the near future
Myeloproliferative
neoplasm can significantly affect the quality of life of the patient.
The complication and treatments as well as the physiological strains
of cancer diagnosis can affect the physical and emotional wellbeing
of patients. Effects of complication vary from depression, fatigue,
pain or depression with suicidal ideation. Moreover, patients can
experience few or no symptoms for a longer period of time. MPNs can
be cured with proper monitoring and treatment. There has been a major
revolution in the management of MPNs by introduction of JAK1 and JAK2
inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in
order to manage MPNs. The drug has also been proven as an alternative
therapy for the treatment of polycythemia vera. Further, the
therapeutic armamentarium for MPN is still inadequate for
normalization of life span, reduction in cardiovascular
complications, and prevention of hematological progression.
Rising awareness of
molecular abnormalities and cellular pathways involve in the
pathogenesis of MPNs is expected to facilitate the development of
clinical trials with novel drugs, either alone or in combination with
ruxolitinib. Interferon (IFN) is a drug that has proven as an
effective alternative for MPNs patients. Better understanding of its
mechanism of action for MPNs could lead to better interferon compound
and potential drugs. In 2017, MPN research foundation have initiated
a MPNRF Interferon (IFN) multi-center project which is expected to
bring together internationally recognized experts to determine
cytokine-driven pathways that affect the path of the MPNs. It is a
closely-related group of progressive blood cancer which is also among
the lucrative opportunities for major players in the
Myeloproliferative Neoplasms treatment market.
Collaboration
among the biotech and pharmaceutical companies to identify new drugs
for MPNs is expected to accelerate the market growth
Novartis AG and
Incyte Corporation are among the key players in Myeloproliferative
Neoplasms treatment market. According to MPN research foundation,
biotech and pharmaceutical companies are expected to propel the
demand for improved treatments and quickly connecting patients with
latest treatment options. It is expected to lead developing
relationships with biotech and pharmaceuticals companies to identify
new areas for scientific exploration. For instance, Incyte
Corporationis is developing inhibitor for Janus Kinase (JAK) and also
focusing on the discovery, development, and commercialization of
proprietary therapeutics globally.
Click To Read
More On Myeloproliferative
Neoplasms Treatment
Also, Coherent
Market Insights has a proprietary database of pipeline biologics and
biosimilars, called PHASE-XS. This database provides analytical data
in addition to the clinical information of ongoing trials for
biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database, kindly click on the
below link or contact at sales@coherentmarketinsights.com
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment